[Federal Register Volume 60, Number 204 (Monday, October 23, 1995)]
[Notices]
[Pages 54377-54378]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-26264]



=======================================================================
-----------------------------------------------------------------------

GENERAL SERVICES ADMINISTRATION


Notice of Intent To Prepare an Environmental Impact Statement for 
the Construction of the Headquarters for the Food and Drug 
Administration

    Pursuant to section 102(2)(C) of the National Environmental Policy 
Act (NEPA) of 1969 as implemented by the Council on Environmental 
Quality regulations (40 CFR parts 1500-1508), and the General Services 
Administration (GSA) guidelines PBS1095.4B, GSA and the Food and Drug 
Administration (FDA) announce their intent to prepare an Environmental 
Impact Statement (EIS) to determine the feasibility of consolidating 
the FDA on the site of the Naval Surface Warface Center in White Oak, 
Maryland. The consolidation would consist of the construction of 
approximately 2 million square feet of office and laboratory space to 
house approximately 5,900 FDA employees.
    GSA will open a formal scoping period for this project from October 
20 to November 20, 1995. This scoping period will be used to identify 
the issues to be addressed in the EIS. A 

[[Page 54378]]
public scoping meeting will be held at 7:30 p.m. on November 7, 1995 at 
the Naval Surface Warfare Center at White Oak, 10901 New Hampshire 
Avenue, in Silver Spring, Maryland. A short formal presentation will 
precede the request for public comments.
    GSA and FDA representatives will be available at this meeting to 
receive comments from the public regarding issues of concern. It is 
important that Federal, State, and County Agencies, interested 
individuals and groups take this opportunity to identify environmental 
concerns and significant issues that should be addressed in the EIS. In 
the interest of available time each speaker will be asked to limit oral 
comments to five minutes.
    Agencies and general public are also invited and encouraged to 
provide written comments in addition to, or in lieu of comments at the 
public scoping meeting. Scoping comments should clearly describe 
specific issues or topics regarding the FDA Headquarters development, 
which the commentator believes the EIS should address. Written 
statements concerning the alternatives should be post-marked no later 
than November 20, 1995, to Ms. Eva Hegedus, Portfolio Management 
(WPTP), National Capital Region, General Services Administration, 7th 
and D streets SW, Washington, DC 20407, Telephone (202) 708-8591; Fax 
(202) 708-7671.

    Dated: October 16, 1995.
Jack Finberg,
Branch Chief, Portfolio Management (WPT).
[FR Doc. 95-26264 Filed 10-20-95; 8:45 am]
BILLING CODE 6820-23-M